We’re proud to share that IVRS AB and Succipro S.L. have received Eurostars funding to develop a new biologic therapy for Crohn’s disease, an important step toward more precise and effective treatments for inflammatory bowel disease (IBD).
This collaboration brings together Succipro’s expertise in biologic drug development and IVRS’s advanced in vivo imaging capabilities, creating a powerful partnership to drive innovation in IBD research.
Succipro is leading the development of EngiSD1, a promising biologic designed to modulate immune cell activity and reduce intestinal inflammation.
IVRS is developing an advanced in vivo imaging model to track IBD progression and treatment response. The approach allows real-time visualization of inflammation and therapeutic effects in living systems.
This milestone marks the beginning of an exciting collaboration and reflects our shared commitment to advancing innovation in IBD research.
https://www.linkedin.com/embed/feed/update/urn:li:share:7391825582507880448
